Literature DB >> 24890134

Overlapping allograft for primary or salvage bone tumor reconstruction.

Dae-Geun Jeon1, Won Seok Song, Wan Hyeong Cho, Chang-Bae Kong, Sang Hyun Cho, Sung Woo Choi, Soo-Yong Lee.   

Abstract

BACKGROUND: Compared with end-to-end allograft coaptation, overlapping allograft offer a superior union rate by increasing the contact area. However, reports on overlapping allograft are scarce. Therefore, we attempted to confirm the usefulness of this technique either after primary tumor resection or in salvaging a failed reconstruction.
METHODS: We analyzed the outcome of 35 overlapping allografts reconstructions. Indications were primary reconstruction of a skeletal defect (n = 19) and salvage of a failed reconstruction (n = 16). Graft survival, union rate, and time to union were evaluated as a function of clinical variables such as age, use of chemotherapy, type of junction, method of fixation, length of overlapped bone, and method of overlapping.
RESULTS: All 35 overlapping allografts showed union at a mean of 5.6 months (range, 3-14 months). One allograft was removed with local recurrence at 19 months post-operatively. Average length of overlapped bone was 3.5 cm (range, 1.4-6.5 cm). Patient age <15-years (P = 0.001) and circumferential overlapping (P = 0.011) shortened the time to union.
CONCLUSIONS: In terms of graft failure rate, union rate, and time to union, overlapping allograft is an excellent technique, which overcomes the limitations of end-to-end fixation.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  allograft; bone tumor; overlapping

Mesh:

Year:  2014        PMID: 24890134     DOI: 10.1002/jso.23669

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  New 3-dimensional implant application as an alternative to allograft in limb salvage surgery: a technical note on 10 cases.

Authors:  Jong Woong Park; Hyun Guy Kang; June Hyuk Kim; Han-Soo Kim
Journal:  Acta Orthop       Date:  2020-05-12       Impact factor: 3.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.